Hikma Pharmaceuticals Plc (HIK) Price Target Cut to GBX 2,500 by Analysts at Jefferies Group
Hikma Pharmaceuticals Plc (LON:HIK) had its price target lowered by investment analysts at Jefferies Group from GBX 2,990 ($39.82) to GBX 2,500 ($33.30) in a report released on Monday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price suggests a potential upside of 18.15% from the company’s previous close.
Several other research firms also recently weighed in on HIK. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 2,550 ($33.96) target price on shares of Hikma Pharmaceuticals Plc in a report on Tuesday, August 16th. Barclays PLC reissued an “overweight” rating and issued a GBX 2,800 ($37.29) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 4th. Numis Securities Ltd initiated coverage on Hikma Pharmaceuticals Plc in a report on Friday, July 22nd. They issued an “add” rating and a GBX 2,830 ($37.69) target price for the company. Morgan Stanley reduced their target price on Hikma Pharmaceuticals Plc from GBX 2,700 ($35.96) to GBX 2,500 ($33.30) and set an “equal weight” rating for the company in a report on Friday, August 12th. Finally, Citigroup Inc. downgraded Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($34.63) target price for the company. in a report on Thursday, August 4th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Hikma Pharmaceuticals Plc currently has an average rating of “Buy” and an average target price of GBX 2,520.90 ($33.58).
Hikma Pharmaceuticals Plc (LON:HIK) traded down 0.80% during mid-day trading on Monday, reaching GBX 2116.00. 508,620 shares of the company’s stock traded hands. The stock’s market cap is GBX 4.78 billion. The company has a 50 day moving average price of GBX 2,273.76 and a 200-day moving average price of GBX 2,221.42. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,575.00 and a 12 month high of GBX 2,703.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/hikma-pharmaceuticals-plc-hik-price-target-cut-to-gbx-2500-by-analysts-at-jefferies-group.html
In other Hikma Pharmaceuticals Plc news, insider Darwazah,Said bought 200,000 shares of the company’s stock in a transaction on Friday, August 26th. The shares were bought at an average price of GBX 2,160 ($28.77) per share, for a total transaction of £4,320,000 ($5,753,862.55). Also, insider Darwazah,Mazen bought 150,000 shares of the company’s stock in a transaction on Friday, June 24th. The shares were acquired at an average price of GBX 2,200 ($29.30) per share, for a total transaction of £3,300,000 ($4,395,311.67).
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com’s FREE daily email newsletter.